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ABSTRACT 
 
Novel approaches to drug delivery and formulation using nanotechnology are revolutionizing 
the future of medicine. The application of nanotechnology in medicine is offering many 
exciting possibilities in healthcare. Engineered nanoparticles and conjugation of monoclonal 
antibodies with anticancer drug Docetaxel have the potential to revolutionize the diagnosis 
and the therapy of its diseases, particularly by targeted delivery of anticancer drugs and 
imaging contrast agents. Prostate cancer, the second most common cancer in men, represents 
one of the major epidemiological problems, especially for patients in the advanced age. There 
is a substantial interest in developing therapeutic options for treatment of prostate cancer 
based on use of nanocarriers with the conjugation of drug and antibody, to overcome the lack 
of specificity of conventional chemotherapeutic agents as well as for the early detection of 
precancerous and malignant lesions. In this article, we highlight on the recent development of 
bioconjugation of drug with nanotechnology strategies adopted for the management of 
prostate cancer. In particular, the combination of targeted and controlled-release polymer 
nanocarriers have worked against prostate specific membrane antigen, a promising targeted 
Docetaxel-loaded nanoparticles, which can be validated for use in the prostate cancer therapy. 
However, several limitations facing nanoparticle delivery to solid tumors, such as 
heterogeneity of intratumoural barriers and vasculature, cytotoxicity and or hypersensitivity 
reactions to currently available cancer nanomedicines, and the difficult in developing targeted 
nanoparticles with optimal biophysicochemical properties, should be still addressed for 
successful tumor eradication. 
 
Introduction 
 
 
The American Cancer Society estimates that approximately 
218,000 men will be diagnosed with, and 32,000 men will die 
of, prostate cancer in the United States in 2014[1] . To give 
these numbers context, prostate cancer (PCa) is the most 
commonly diagnosed cancer in men and is responsible for the 
second highest number of cancer related deaths in men in the 
United States. PCa represents 27.6% of new cancer cases in 
men and 10.7% of cancer related deaths in men [1]. An 
estimated 1 in 3 men will be diagnosed with PCa or a 
precancerous prostatic lesion in their lifetime [2]. In Europe, 
there are approximately 346,000 new PCa cases and 87,000 
deaths per year [3]. PCa is largely dependent on androgens for 
growth and proliferation; hence, androgen deprivation therapy 
(chemical castration) is the standard of treatment, and it 
generally causes prostate tumors to regress. However, most 
PCa cases eventually recur after treatment. These more lethal 
cases generally have a high Gleason score and can be 
metastatic and/or refractory to androgen deprivation therapy 
(castration resistant). Skeletal metastasis is the most 
significant cause of morbidity and mortality in PCa [4]. 
Skeletal metastases are found in approximately 90% of 
patients who die of PCa [5]. This adds to the health burden of 
these patients while they are still alive, due to painful lesions 
that impair mobility and cause pathologic fractures, spinal 
cord compression, and symptomatic hypercalcemia [6]. The 
frequency of bone metastases in PCa indicates that the 
microenvironment of the bone may promote the growth of 
PCa cells. The proportion of active osteoblasts is usually 
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greater than that of active osteoclasts in PCa bone metastases, 
resulting in the net formation (rather than lysis) of bone in a 
majority of these lesions [7]. However, osteolysis is required 
for metastatic tumor cells to invade the bone matrix. Also, 
patients with bone metastases have a higher risk of fracture, 
indicating that bone destruction is occurring. One study 
suggests that there may be more bone lysis during prostate 
tumor metastasis than originally thought and that it might be 
more prevalent in PCa than other diseases [8]. While much 
work has been done in area of prostate tumor-bone crosstalk 
[9–11]. There is still much to learn in this area. Accordingly, 
there is an urgent need for new treatments and better 
experimental models for the study of PCa development, 
progression, and metastasis. 
 
Prostate cancer is the second leading cause of cancer death in 
men and accounts for approximately 30% of all new cancer 
diagnoses in men More than 70% of all cancer deaths in 2005 
occurred in countries like India. Deaths from cancer in the 
world are projected to continue rising, with an estimated 9 
million people dying from cancer in 2015 and 11.4 million 
dying in 2030. Prostate-specific membrane antigen (PSMA), 
also named glutamate carboxypeptidase II (GCPII), is a classic 
type II membrane glycoprotein and is perhaps the most 
important enzyme-biomarker and target in prostate cancer 
research. PSMA can be induced for internalization by bound 
antibodies or small-molecule inhibitors. Its extracellular 
domain possessing folate hydrolase and N-acetylated-alpha-
linked-acidic dipeptidase (NAALADase) activities can serve 
as binding target for antibodies, inhibitors and aptamers. 
Every single cell that moves to other place may develop into 
new tumor giving rise to various necrotic regions. Upon 
treatment even if a single cell or colony is left out, it can again 
lead to entire tumor. Present cancer therapy should be based 
on the philosophy, “even a single cancer cell should not 
remain untreated in the body and nothing less than complete 
elimination of tumor from an individual can be accepted”. 
This forms the objective behind chemotherapy.  
Tumor Physiology and Vasculature 
To understand prostate cancer, it helps to know something 
about the prostate and nearby structures in the body. The 
prostate is a gland found only in males. It is located in front of 
the rectum and below the urinary bladder. The size of the 
prostate varies with age. In younger men, it is about the size of 
a walnut, but it can be much larger in older men.   
 
Fig 1: Tumor physiology 
Prostate cancer forms in a gland in the male reproductive 
system found below the bladder and in front of the rectum. 
The male sex hormone testosterone stimulates the prostate 
tumors to grow. According to the National Cancer Institute, an 
estimated 238,590 men will be diagnosed with prostate cancer 
and 29,720 will die from the disease in 2014. The prostate's 
job is to make some of the fluid that protects and nourishes 
sperm cells in semen, making the semen more liquid. Just 
behind the prostate are glands called seminal vesicles that 
make most of the fluid for semen. The urethra, which is the 
tube that carries urine and semen out of the body through the 
penis, goes through the center of the prostate. The prostate 
starts to develop before birth. It grows rapidly during puberty, 
fueled by male hormones (called androgens) in the body. The 
main androgen, testosterone, is made in the testicles. The 
enzyme 5-alpha reductase converts testosterone into 
dihydrotestosterone (DHT). DHT is the main hormone that 
signals the prostate to grow. The prostate usually stays at 
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about the same size or grows slowly in adults, as long as male 
hormones are present.  Under normal conditions, the cells 
reproduce, grow, divide, multiply and eventually undergo 
apoptosis. This maintains proper balance and functioning of 
the organs.  
On the other hand tumors bear highly irregular complex 
architectural vasculature. The genesis of blood vessels is an 
abnormal state as there is abrupt formation of newer vessels 
and existing vessels tend to become disorganized. Such 
eruptions occur as a result of genetic aberrations from pre-
existing vessels or in specialized microenvironment from 
endothelial cell progenitors of bone marrow [45-47]. Upon 
undergoing change in organizational pattern of a gene the 
normal cell cycle is disrupted. The gene (proto-oncogene) is 
thus converted into oncogene and loses its normal growth 
regulation. As a consequence of mutations abnormal growth 
and proliferation of cells begin along with the expression of 
various surface markers and proteins, which facilitate their 
growth and supplement the cells with necessary nutrients and 
oxygen at the expense of normal cells. The abnormal signal 
Nanoparticles proteins may induce faster proliferation of cells 
via transcription. Thus, a normal cell on being converted into 
oncogene proliferates under the stimuli of these agents and 
leads to metastatic tumors [48]. Blood from the capillaries 
may diffuse or drain out into a newer network consisting of 
vessels and lymph nodes called lymphatic system, which 
circulates like blood in various tissues and organs. Blood and 
lymph communicate to each other at lymph nodes and the 
lymph, via thoracic vein finally enters the general circulation. 
Lymphatic metastasis is characteristic of tumors. Metastasis is 
movement of tumors to other sites and is highly hazardous 
state of bio-system. Every single cell that moves to other place 
may develop into new tumor giving rise to various necrotic 
regions. Upon treatment even if a single cell or colony is left 
out, it can again lead to entire tumor.  
The prostate is a secretary organ; it produces approximately 
20% of the seminal fluid. Prostatic secretion contributes to 
sperm function, but is not mandatory to the fertilizing capacity 
of sperm. Progression of prostate cancer is a multistep process, 
and its mechanisms are poorly understood. Prostate cancer 
usually occurs in the peripheral zone [12], while BPH often 
occurs in the transition zone of the   prostate. Commonly 
occurring chronic inflammation [13] may predispose the tissue 
to the development of malignant changes, although the 
concept that inflammation can promote prostate cancer is still 
highly speculative. Prostatic intraepithelial neoplasia (PIN) is 
considered a precursor of prostate cancer. Prostate cancer can 
be screened by means of the prostate-specific antigen (PSA) 
test; however, the actual cancer diagnosis is based on the 
histological or cytological examination of biopsy samples. 
Cancer of the prostate gland is one of the most frequently 
diagnosed cancers amongst Western men, as well as men in 
most developing countries. According to figures available 
from the American Cancer Society, prostate cancer (PCa) has 
surpassed heart disease as the top killer of men over the age of 
85 years [14]. Treatment of advanced PCa relies mainly on 
non-specific therapies, such as chemotherapies and ionizing 
radiation, which have low efficacy and are highly toxic to 
normal tissues [15].  
Role of tumor targeted therapy on prostate cancer 
Targeted therapy is potentially an important means of 
attacking cancer. Better outcomes for hormone resistant 
tumors may be achieved by specifically delivering drugs, 
antigens or toxins to tumors to specifically kill tumor cells 
without affecting surrounding tissue. Targeted therapy is 
dependent on specific marker for the cancer cells that can be 
identified with affinity agents such as antibodies for antigens. 
One of the targeting agents associated with the prostate is 
prostate specific membrane antigen (PSMA). Several anti-
PSMA monoclonal antibodies (MoAbs) that bind the 
extracellular PSMA domain have been developed. To improve 
the pharmacokinetics properties and the bioavailability of 
these chemo preventive agents, tremendous advancement has 
been made by making NP-based therapeutic products [16-17].  
Nanotechnology based therapeutic systems have attracted 
tremendous attention as they have the potential to 
revolutionize cancer therapy and diagnosis owing to their 
tumor-targeting ability that allows anti-cancer drugs to be 
delivered more specifically to the cancer cells, thus greatly 
enhancing the therapeutic outcomes while minimizing any 
non-specific systemic toxicity [18]. Several recent studies 
have already demonstrated that prevention and therapy of PCa 
using Nanomedicine may be a viable option for decreasing the 
mortality and morbidity associated with the disease [19]. NPs 
have the potential to offer solutions to the cur-rent obstacles in 
cancer therapies, because of their unique size (i.e. in general 
1–1000 nm – or at least one dimension sized from 1 to 100 
nm, preferably in the 5–200 nm range for medical purpose) 
and large surface-to-volume ratios. In fact, the size, surface 
characteristic and shape of a nanoparticle (NP) play a key role 
in its biodistribution in vivo [20]. 
Monoclonal antibodies 
One way the immune system normally attacks foreign 
substances in the body is by making large numbers of different 
antibodies. An antibody is a “sticky” protein that targets a 
specific antigen. Antibodies circulate in the body until they 
find and attach to the antigen. Once attached, they recruit 
other parts of the immune system to destroy the cells 
containing the antigen. Many copies of a specific antibody can 
be made in the lab. These are known as monoclonal antibodies 
(MAbs). These antibodies can be useful in fighting diseases 
because they can be designed specifically to only target a 
certain antigen, such as one that is found on cancer cells. 
Monoclonal antibodies are now used to treat many diseases, 
including some types of cancer. A major advantage of these 
drugs is that because they are so specific, they may have only 
mild side effects, unlike some other cancer treatments. But 
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researchers first have to identify the right antigen to attack. 
For cancer, this is not always easy, and so far MAbs have 
proven to be more useful against some cancers than others. 
Over the past 15 years or so, the US Food and Drug 
Administration (FDA) have approved about a dozen mAbs to 
treat certain cancers. As researchers have found more antigens 
that are linked to cancer, they have been able to make 
monoclonal antibodies against more and more cancers. 
Clinical trials of newer mAbs are now being done on many 
types of cancer [49]. 
Types of monoclonal antibodies 
Two types of monoclonal antibodies are used in cancer 
treatments: 
 Naked MAbs are antibodies that work by themselves. 
There is no drug or radioactive material attached to 
them. These are the most commonly used MAbs at 
this time. 
 Conjugated MAbs are those joined to a chemotherapy 
drug, radioactive particle, or a toxin (a substance that 
poisons cells). These mAbs work, at least in part, by 
acting as homing devices to take these substances 
directly to the cancer cells. 
Naked monoclonal antibodies 
Most naked MAbs attach to antigens on cancer cells, but some 
work by binding to antigens on other, non-cancerous cells, or 
to even free-floating proteins. Naked MAbs can work in 
different ways. Some may boost a person’s immune response 
against cancer cells. Others work by blocking specific proteins 
that help cancer cells grow. Some naked MAbs attach to 
cancer cells to act as a marker for the body's immune system 
to destroy them. An example of this is alemtuzumab 
(Campath®), which is used to treat some patients with chronic 
lymphocytic leukemia. Alemtuzumab is an antibody that binds 
to the CD52 antigen, which is found on immune cells called B 
cells and T cells. Once attached, the antibody triggers the 
destruction of the cell by the immune system. Some naked 
mAbs work mainly by attaching to and blocking specific 
antigens that are important signals for cancer cells (or other 
cells that help cancer cells grow or spread). For example, 
trastuzumab (Herceptin®) is an antibody against the HER2/neu 
protein. A large amount of this protein is present on the cells 
in some types of cancer. When HER2/neu is activated, it helps 
these cells grow. Trastuzumab stops these proteins from 
becoming active. It is used to treat breast and stomach cancers 
that have large amounts of this protein.  
Conjugated monoclonal antibodies 
Monoclonal antibodies attached to a radioactive substance, 
drug, or toxin, are called conjugated MAbs. The MAb is used 
as a homing device to take one of these substances directly to 
the cancer cells. The MAb circulates in the body until it can 
find and hook onto the target antigen. It then delivers the toxic 
substance where it is needed most. This lessens the damage to 
normal cells in other parts of the body. Conjugated MAbs are 
also sometimes referred to as tagged, labeled, or loaded 
antibodies. They can be divided into groups depending on 
what they are linked to. 
 MAbs with radioactive particles attached are referred 
to as radio labeled, and treatment with this type of 
antibody is known as radio immunotherapy (RIT).  
 MAbs with chemotherapy drugs attached are referred 
to as chemo labeled. 
 MAbs attached to cell toxins are called 
immunotoxins. 
Radio labeled antibodies 
Radio labeled antibodies have small radioactive particles 
attached to them. Ibritumomab tiuxetan (Zevalin®) and 
tositumomab (Bexxar®) are examples of radio labeled mAbs. 
Both of these are antibodies against the CD20 antigen, but 
they each have a different radioactive particle attached. They 
deliver radioactivity directly to cancerous B cells and can be 
used to treat some types of non-Hodgkin lymphoma. 
Chemo labeled antibodies 
These MAbs have powerful chemotherapy drugs attached to 
them. The chemotherapy drug is often too powerful to be used 
on its own; it would cause too many side effects if not 
attached to a MAb. There are only 2 chemo labeled antibodies 
approved by the FDA to treat cancer at this time: brentuximab 
vedotin (Adcetris®) and ado-trastuzumab emtansine 
(Kadcyla™). Brentuximab vedotin is made up of an antibody 
that targets the CD30 antigen (found on B cells and T cells), 
attached to a chemo drug called MMAE. It is used to treat 
Hodgkin lymphoma and anaplastic large cell lymphoma that is 
no longer responding to other treatments. Ado-trastuzumab 
emtansine is made of an antibody that targets the HER2 
protein attached to a chemo drug called DM1. It is used to 
treat advanced breast cancer in patients whose cancer cells 
have too much HER2. 
Immunotoxins 
These MAbs have cell poisons (toxins) attached to them, 
which makes them similar in many ways to chemo labeled 
mAbs. At this time no immunotoxins are approved to treat 
cancer, although many are being studied. However, a related 
drug known as denileukin diftitox (Ontak®) is being used to 
treat some cancers. It consists of an immune system protein 
known as interleukin-2 (IL-2) attached to a toxin from the 
germ that causes diphtheria. Although it’s not a MAb, IL-2 
normally attaches to certain cells in the body that contain the 
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CD25 antigen, which makes it useful for delivering the toxin 
to these cells. Denileukin diftitox is used to treat lymphoma of 
the skin (also known as cutaneous T-cell lymphoma). It is also 
being studied to be used against a number of other cancers.  
Antibody-drug conjugates 
The first FDA approved ADC was Mylotarg (gemtuzumab 
ozogamicin) and was initially developed by Wyeth in 2000 for 
the treatment of acute myeloid leukemia. After a decade, it 
was withdrawn from the market due to an undesirable efficacy 
and safety profile. Mylotarg targeted the CD33 receptor which 
turned out to be nonselective for tumor cells [21]. 
Additionally, the linker used to attach the drug to the antibody 
was unstable and the drug was released prior to reaching its 
target [22]. Since this failure, huge strides have been made in 
the science of properly binding antibodies to drugs. By using 
linkers with an acceptable biological half-life, researchers 
ensure that ADCs can reach the targeted cell with limited side 
effects [23]. In 2011, the U.S. Food and Drug Administration 
(FDA) approved Seattle Genetics Adcetris (brentuximab 
vedotin) to treat Hodgkin’s lymphoma and systematic 
anaplastic large-cell lymphoma [24]. This ADC made about 
$34.5 million in the first quarter of 2012 and revenues 
continue to bolster. Use of ADCs is anticipated to increase 
nearly 50% over the next decade just in the oncology market.  
Roche and Genentech alone have over 25 ADCs in their 
pipeline, including nine in clinical trials [25]. The first 
potential blockbuster ADC reached the market in February 
2013 when the Kadcyla (trastuzumab emtansine, T-DM1) was 
approved for the treatment of metastatic breast cancer. 
Kadcyla combines the breast cancer treatment antibody 
Herceptin (trastuzumab) with the cytotoxic payload 
mertansine (DM1), a drug licensed from ImmunoGen. The 
projected sales for the treatment are in the region of $2 to $5 
billion per year. The continued success of the ADC 
technology platform is due to the collaborations within 
biopharma and the promising clinical trials [25]. These 
collective results indicate a commitment towards targeted 
therapeutic delivery using humanized monoclonal antibody 
technologies [26]. To date, most of the drugs utilized in the 
development of ADCs use auristatins (Seattle Genetics) or 
maytansine (ImmunoGen) [27] but other emerging payloads 
are in development from Spirogen such as 
pyrrolobenzodiazepines (PBDs) for the next generation of 
antibody-drug conjugates [28]. 
 
Antibody-drug conjugates mechanism of action 
A typical ADC consists of a monoclonal antibody which is 
capable of binding to the surface of tumor cell-specific 
antigens [29]. These can include proteins on the surface of the 
B and T cells of the immune system, such as CD20 and CD22, 
the human epidermal growth factor receptor 2 (HER2), or 
prostate-specific membrane antigen (PSMA) [30]. This 
specific antibody is attached to a cytotoxic drug via a 
cleavable linker [31]. The drug is designed to induce tumor 
cell death by causing irreversible DNA damage or interfering 
with cell division [32]. The mechanism of action of ADCs is 
the ability of the antibody to recognize and bind with a 
specific antigen. This binding initiates a cascade of events 
(Stages 1 to 5) via the process called endocytosis whereby the 
cell’s lysosomal enzymes release the cytotoxic drug to kill 
tumor cells (Figure 2) [33]. 
 
 
Fig 2: Schematic representation of the ADC internalization process 
Nanotechnology approaches to target to Prostate Tumor 
In this context, Sanna et al.2011 [34], developed novel 
targeted polymeric encapsulated NPs, densely decorated by 
low molecular weight organic molecule as targeting ligands in 
their polymeric [poly(lactide-co-glycolide)-PEG, PLGA-PEG] 
shell surface, to selectively bind to prostate specific membrane 
antigen (PSMA) [35]. These functionalized NPs exhibited a 
selective in vitro efficacy against PSMA-expressing Prostate 
Cancer cells PC3 and DU145 with respect to the non-
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functionalized ones, without affecting normal cell viability. 
Other different nanosystems, such as polysaccharide NPs, 
were studied as drug delivery vehicles for chemo protective 
agents [36]. These NPs retained biological activity, thus 
reducing the cell viability and inducing apoptosis of PC3 and 
DU145 cells. In vitro assay further demonstrated that 
encapsulation of monoclonal conjugated Nanoparticles 
enhanced its inhibitory effect on cell proliferation at lower 
concentrations, compared with free antigens.  
As for the development of “nanobioconjuated tumor targeted 
therapy” to be used in PCa therapy, a major effort has been 
done by the team led by Langer and Farokhzad, that designed 
customized controlled-release NPs, loaded with the 
chemotherapeutic agent Docetaxel (DTXL), constituted by 
several safe or Food Drug Administration (FDA) approved 
materials as biocompatible polymers (PLGA, PEG, etc.), each 
one performing a specific function in the final NP prototype 
[37-38]. For example, hydrophilic spacer (i.e. PEG) were 
incorporated into the NP’s outer shell, in order to have a 
minimal self–self and self–nonself interaction, to prevent NP 
loss to undesired location, and to escape macrophage capture, 
enabling “stealth” properties for immune evasion. The results 
indicated that the encapsulated drug efficiently interacted to 
the tumor and selectively delivered DTXL to PCa cells. This 
approach strongly contributed to the development of targeted 
NPs as highly selective and effective therapeutic modalities 
for PCa treatment.  
The researchers observed that injection of NP-gene complexes 
led to significant decrease in the sizes of the prostate gland 
and the prostate tumor, whereas direct injection of the gene 
construct alone produced no effects on the tumor growth. A 
novel method for combining Taxol (Paclitaxel) chemotherapy 
and Herceptin (a monoclonal antibody) to generate a treatment 
for advanced PCa has been developed by the Goldstein’s 
group [34, 39]. Since the HER2 receptor is over expressed in 
some PCa cells, the Herceptin (Trastuzumab) antibody has 
been considered as a putative targeting agent.  
 
General nanoparticle characteristics  
The size, surface characteristics and shape of a nanoparticle 
play a key role in its biodistribution in vivo. Spherically 
shaped, passively targeted, nanoparticle less than 5 nm in 
diameter are rapidly cleared from circulation via 
extravasations or renal clearance, and as particle size increases 
from the nanometer range to ~15 micrometers, accumulation 
occurs primarily in the liver, spleen and bone marrow. 
Nanoparticle behavior in the size range ~10 nm to ~15 
micrometers varies widely in terms of biodistribution and 
cellular uptake of nanoparticle in this range is heavily 
dependent on cell type. Under normal circumstances, 
nanoparticle are mechanically filtered by sinusoids in the 
spleen and removed from circulation via cells of the 
reticuloendothelial system (RES). In addition, Kuppfer cells in 
the liver, also part of the RES, play a key role in particle 
removal [42]. The propensity for accumulation of nanoparticle 
in cells of the RES is dictated by specific proteins adsorbed in 
vivo to the particle surface, which can be influenced through 
modifications of surface characteristics. This process of 
protein adsorption, known as opsonization, begins 
immediately after particles come in contact with plasma. The 
exact nature of the types and quantities of proteins and their 
conformations dictate the body’s reaction. The mechanisms 
involved in this process are not well understood; however, the 
major opsonins are known. Immunoglobulin (Ig) and 
complement proteins are the predominant contributors to the 
recognition of foreign particles by the cells of the RES (that is, 
macrophages). Complement activation can further complicate 
targeted drug delivery by inducing hypersensitivity reactions. 
Finally, particulate matter larger than ~15 micrometers is 
removed from circulation via mechanical filtration in 
capillaries and can be lethal depending on dose [43]. 
Current methods for addressing the negative attributes 
associated with opsonization have focused almost exclusively 
on slowing the process by rendering the particle surface more 
hydrophilic or by neutralizing surface charge. The 
predominant strategy has been to adsorb or graft a hydrophilic 
polymeric coating, such as polyethylene glycol (PEG) to the 
surface of the particle. These polymer chains, depending on 
density, act as a steric brush that imparts resistance to protein 
adsorption. However, the PEG effect is transient, so eventual 
opsonization and macrophage clearance still occur [44]. 
 
Nanocarrier Conjugates 
Due to their unique architecture and available surface groups, 
(PLGA) [poly (lactide-co-glycolide) nanocarriers have been 
used as a backbone for the attachment of several types of 
biologic material. The resulting conjugates have applications 
in a number of different areas of biology and medicine. Some 
of the earlier work done in this area documented that 
antibodies can direct nanocarrier-associated therapeutic agents 
to antigen-bearing tumors. Nanocarriers have also been 
conjugated to fluorochromes and shown to enter cells and can 
be detected. The current work combines these features to show 
that anti-PSMA antibody dendrimer conjugates can be used 
for targeting prostate cancer cells. 
 
Ultimate outcomes 
Major progress in the recombinant gene technology has 
opened access to human-compatible MAbs, which provides 
significant advantages for the MAb-based tumor targeting. 
The validity of this approach has been proven by the success 
of Mylotarg, which was approved by the FDA as well as the 
fact that more than several MAb-drug conjugates are in 
various stages of human clinical trials. Major challenges for 
MAb-based drug delivery include the identification of target 
antigens that are over expressed specifically on the tumor 
surface, the circumvention of potential immunogenicity of the 
conjugates, and the determination of the right size of the 
conjugates that can penetrate into tumors, yet not to be cleared 
by kidneys too fast.  
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Monoclonal antibody based targeting has a high potential for 
tumor specific drug delivery of cytotoxic agents. Since most 
prostate cancers are difficult to treat due to their multidrug-
resistance, this approach may shed a light on the development 
of efficacious chemotherapy. One of the inherent problems is 
the stability of these peptides in circulation, although this can 
be solved by appropriate design and modifications to prevent 
or slow down the amide hydrolysis. The efficacies 
demonstrated in the animal models show great promise in this 
approach. However, the detailed mechanism of tumor-
targeting by biodegradable polymeric naocarriers needs to be 
clarified.  
As described above, tumor-targeting drug delivery in cancer 
therapy has been evolving from the traditional chemotherapy 
with the hope to minimize undesirable side effects and 
improve the quality of life of cancer patients. The authors 
sincerely hope that some breakthroughs come out of this line 
of approaches for new and efficacious cancer chemotherapy. 
 
Conclusions and perspectives  
Nanotechnologies are demonstrating significant impact on 
drug delivery over about the last 20 years; several first-
generation of therapeutic NP products are commercially 
available. Active targeting via the inclusion of a specific 
ligand on the NPs is envisioned to provide an effective 
strategy, and some ligand-targeted nanotherapeutics are either 
approved or under clinical evaluation. Focusing on PCa, the 
pioneering work of Farokhzad et al. [37, 41] led to proof-of-
concept for the development of drug delivery vehicles that 
were composed of biocompatible polymeric NPs and aptamers 
to target PSMA. The therapeutic potential of these NPs has 
been explored by in vitro and in vivo studies for targeted 
delivery and uptake of DTXL by PCa cells. The translation of 
these bioconjugates into clinical practice resulted in targeted 
polymeric NPs that have recently entered clinical trials. More 
complex targeted NP systems addressed to the PCa, as well as 
to many cancer diseases, which combine diagnostic and 
therapeutic agents, or that can trigger drug release at the target 
site when exposed to external stimuli, are also going ahead in 
the development process. Despite the great potential of 
nanosystems, there is an increasing effort to overcome several 
limitations that prevent therapeutics and imaging agents from 
reaching target tumors in sufficient concentration. In fact, a 
succession of several membrane layers as biological barriers, 
and a plethora of cellular processes, constitutes important 
obstacles for chemotherapeutic or imaging agents attempting 
to target solid tumors [40-42]. 
NP surface charge is an important factor for activation of the 
complement system, and some polymer coatings were shown 
to reduce complement activation by NPs. Therefore, for NPs 
moving into the clinical evaluation, it is important that 
nanotoxicology research uncovers and understands how these 
factors influence the toxicity of such nanosystems, to avoid 
their undesirable properties. In conclusion, the “magic bullet” 
concept, the first description of the drug-targeting paradigm, is 
beginning to be also applied for treating PCa disease, and 
continued research and development efforts in the 
nanotechnology arena will provide major goals for cancer 
therapy and for human health in the next future.  
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